Robert Copenhaver

Robert Copenhaver has over 15 years of combined experience in pharmaceutical drug development and pharmaceutical business development. The majority of Rob’s experience in drug development has been in the development of monoclonal antibodies for indications in autoimmunity and oncology. As an industry scientist, Rob helped create 4 different molecules that are in late-stage clinical development. Rob also has extensive experience in business development and licensing, including prior work with biotech consulting firm Campbell Alliance, experience in university tech transfer offices, and as an independent consultant. He is currently Director of Intellectual Property & Business Development at DesignMedix. He holds a Master’s of Science from the University of Texas and an MBA with Honors from the University of Houston.